DOCSLIB.ORG

Guidelines-10.1.Finalsept2020.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines-10.1.Finalsept2020.Pdf GUIDELINES Version 10.010.1 NovemberOctober 2020 2019 English Table of Contents Introduction to EACS Guidelines 2020 2 Bone Disease: Screening and Diagnosis 61 Summary of Changes from v10.0 to v10.1 3 Vitamin D Deficiency: Diagnosis and Management 62 Panel Members 4 Approach to Fracture Reduction in PLWH 63 Governing Board Members 4 Kidney Disease: Definition, Diagnosis and Management 64 Abbreviations 5 ARV-associated Nephrotoxicity 65 Indications and Tests for Proximal Renal Tubulopathy (PRT) (66) Green text = online only at http://www.eacsociety.org and in the EACS Guidelines App. Page numbers in brackets refer to corresponding pages in Dose Adjustment of ARVs for Impaired Renal Function 67 the online version of the Guidelines. Work-up and Management of PLWH with 69 Increased ALT/AST Part I Liver Cirrhosis: Classification and Surveillance 70 Liver Cirrhosis: Management 71 Assessment of PLWH at Initial & Subsequent Visits 6 Non-Alcoholic Fatty Liver Disease (NAFLD) 72 Part II Diagnosis and Management of Hepatorenal Syndrome (HRS) (73) Dose Adjustment of ARVs for Impaired Hepatic Function 74 ART of PLWH 9 Lipoatrophy and Obesity: Prevention and Management (75) Assessing PLWH's Readiness to Start and Maintain ART 9 Hyperlactataemia and Lactic Acidosis: Diagnosis, Prevention (76) Recommendations for Initiation of ART in PLWH with Chronic Infection 11 and Management without prior ART Exposure Travel 77 Initial Combination Regimen for ART-naïve Adult PLWH 12 Drug-drug Interactions between Antimalarial Drugs and ARVs (78) Primary HIV Infection (PHI) 14 Vaccination 79 Switch Strategies for Virologically Suppressed Persons 15 Sexual and Reproductive Health of Women and Men Living with HIV 80 Virological Failure 16 Sexual Dysfunction (82) Treatment of Pregnant Women Living with HIV 17 Treatment of Sexual Dysfunction in Men Living with HIV (83) ART in TB/HIV Co-infection 20 Depression: Screening and Diagnosis 84 Post-exposure Prophylaxis (PEP) 22 Depression: Management 85 Pre-exposure Prophylaxis (PrEP) 23 Classification, Doses, Safety and Adverse Effects of Antidepressants 86 Adverse Effects of ARVs & Drug Classes 24 Drug-drug Interactions between Antidepressants and ARVs (87) Algorithm for Diagnosis & Management of Cognitive Impairment in 88 Part III PLWH without Obvious Confounding Conditions Drug-drug Interactions and Other Prescribing Issues in PLWH 26 Chronic Lung Disease in PLWH 89 Drug-drug Interactions between ARVs and Non-ARVs 27 Drug-drug Interactions between Bronchodilators (for COPD) and ARVs (90) Drug-drug Interactions between Antidepressants and ARVs (29) Drug-drug Interactions between Pulmonary Antihypertensives and (91) Drug-drug Interactions between Antihypertensives and ARVs (30) ARVs Drug-drug Interactions between Analgesics and ARVs (31) Frailty in the Context of Ageing 92 Drug-drug Interactions between Anticoagulants/Antiplatelet Agents and (32) Solid Organ Transplantation (SOT) in PLWH (93) ARVs Drug-drug Interactions between Immunosuppressants (for SOT) and (94) Drug-drug Interactions between Bronchodilators (for COPD) and ARVs (33) ARVs Drug-drug Interactions between Contraceptives and ARVs (34) Part V Drug-drug Interactions between Corticosteroids and ARVs (35) Drug-drug Interactions between Antimalarial Drugs and ARVs (36) Clinical Management and Treatment of Viral Hepatitis 95 Co-infections in PLWH Drug-drug Interactions between Pulmonary Antihypertensives and (37) ARVs General Recommendations for Persons with Viral Hepatitis/HIV 95 Co-infection Drug-drug Interactions between Immunosuppressants (for SOT) and (38) ARVs Treatment and Monitoring of Persons with HBV/HIV Co-infection 96 Drug-drug interactions between DAAs and ARVs (39) Treatment and Monitoring of Persons with HCV/HIV Co-infection 97 Administration of ARVs in PLWH with Swallowing Difficulties 40 HCV Treatment Options in HCV/HIV Co-infected Persons 98 Dose Adjustment of ARVs for Impaired Hepatic Function 42 Drug-drug Interactions between DAAs and ARVs (100) Dose Adjustment of ARVs for Impaired Renal Function 43 Algorithm for Management of Recently Acquired HCV Infection in 101 PLWH Selected Non-ARV Drugs Requiring Dosage Adjustment in Renal (45) Insufficiency Cut-off Values of Non-invasive Tests for the Detection of Advanced (102) Fibrosis and Cirrhosis Prescribing in Elderly PLWH 47 Hepatitis D and E in PLWH 103 Selected Top 10 Drug Classes to Avoid in Elderly PLWH (48) Dosage Recommendations for Hormone Therapy when Used at High (49) Part VI Doses for Gender Transitioning Opportunistic Infections 104 Part IV When to start ART in PLWH with Opportunistic Infections (OIs) 104 Prevention and Management of Co-morbidities in PLWH 50 Immune Reconstitution Syndrome (IRIS) 104 Drug Dependency and Drug Addiction (51) Primary Prophylaxis of OIs According to stage of Immunodefficiency 105 Cancer: Screening Methods 52 Primary Prophylaxis, Treatment and Secondary Prophylaxis/Mainte- 106 nance Treatment of Individual OIs Lifestyle Interventions 53 Diagnosis and Treatment of TB in PLWH 114 Prevention of Cardiovascular Disease (CVD) 54 TB Drugs Doses 117 Hypertension: Diagnosis, Grading and Management 55 Hypertension: Drug Sequencing Management 56 References Drug-drug Interactions between Antihypertensives and ARVs (57) Type 2 Diabetes: Diagnosis 58 Video Links (118) Type 2 Diabetes: Management 59 References to all sections (119) Dyslipidaemia 60 EACS European EACS Guidelines 10.1 1 AIDS Clinical Society Introduction to the EACS Guidelines 2020 Welcome to the EACS Guidelines! Each respective section of the Guidelines is managed by a panel of expe- rienced European HIV experts, with additional experts in other fields of ex- These Guidelines were developed by the European AIDS Clinical Society pertise included where necessary. All recommendations are evidence-based (EACS), a not-for-profit organisation, whose mission is to promote excel- whenever possible and based on expert opinions in the rare instances where lence in standards of care, research and education in HIV infection and re- adequate evidence is unavailable. The Guidelines do not provide formal lated co-infections, and to actively engage in the formulation of public health grades of evidence, panels make decisions by consensus or by vote when policy, with the aim of reducing the HIV disease burden across Europe. necessary and we do not publish results of the votes or discrepancies if any occur. The EACS Guidelines were first published in 2005, and are currently avail- able in print, online as a pdf and web-based version, and as a free App for The EACS Guidelines panels are overseen by a Guidelines Chair who both iOS and Android devices. The Guidelines are translated into several dif- serves a three-year term and is elected from the Governing Board. Each ferent languages and are formally revised at least annually for the electronic panel is led by a Panel Chair, supported by a Vice-Chair and a Young version and biennially for the printed version. The electronic version can, Scientist. The Co-Chair will take over the role of Chair after the Chair’s term however, be updated at any time if the panels consider it necessary. expires. Panel membership is reviewed annually and rotation is overseen by the Panel Leads and Guidelines Chair according to a standard The aim of the EACS Guidelines is to provide easily accessible and compre- operating procedure. Operational matters of the EACS Guidelines are led by hensive recommendations to clinicians involved in the care of people living a Coordinator in the Medical Secretariat, supported by the EACS Secretariat. with HIV (PLWH). A list of the main references used to produce the Guidelines is provided as The EACS Guidelines cover a relatively large and diverse area geograph- a separate section, see References. Please reference the EACS Guidelines ically, with different national levels of access to care. As a natural conse- as follows: EACS Guidelines version 10.1, October 2020. Video links to the quence, the Guidelines aim to cover a relatively wide range of recommenda- EACS online course on Clinical Management of HIV are provided throughout tions as opposed to the often more uniform national guidelines. the Guidelines, see Video links. The 2020 version of the Guidelines includes minor updates of all sections. The diagnosis and management of HIV infection and related co-infections, The most essential changes are listed in the Summary of changes from opportunistic diseases and comorbidities continue to require a multidiscipli- v10.0 to v10.1 nary effort for which we hope the 2020 version of the EACS Guidelines will provide you with an easily accessible and updated overview. All comments to the Guidelines are welcome and can be directed to [email protected] We wish to warmly thank all panellists, external experts, linguists, transla- tors, the EACS Secretariat, the Sanford team and everyone else who helped to build up and to publish the EACS Guidelines for their dedicated work. Enjoy! Georg Behrens and Lene Ryom October 2020 EACS European EACS Guidelines 10.1 2 AIDS Clinical Society Summary of Changes from v10.0 to v10.1 The COVID-19 situation is rapidly changing, and evidence is constantly Viral Hepatitis Co-infections section accumulating. Therefore, we refer to the regularly updated BHIVA, DAIG, EACS, GESIDA & Polish Scientific AIDS Society Statement on risk of • The main tables on HCV treatment options and DDIs have been updated, COVID-19 for PLWH https://www.eacsociety.org/home/covid-19-and-hiv.html pages 98-100 • Resistance testing guidance before
Load more

Recommended publications
  • NIH Public Access Author Manuscript Pharmacol Ther
    NIH Public Access Author Manuscript Pharmacol Ther. Author manuscript; available in PMC 2010 August 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacol Ther. 2009 August ; 123(2): 239±254. doi:10.1016/j.pharmthera.2009.04.002. Ethnobotany as a Pharmacological Research Tool and Recent Developments in CNS-active Natural Products from Ethnobotanical Sources Will C. McClatcheya,*, Gail B. Mahadyb, Bradley C. Bennettc, Laura Shielsa, and Valentina Savod a Department of Botany, University of Hawaìi at Manoa, Honolulu, HI 96822, U.S.A b Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, U.S.A c Department of Biological Sciences, Florida International University, Miami, FL 33199, U.S.A d Dipartimento di Biologia dì Roma Trè, Viale Marconi, 446, 00146, Rome, Italy Abstract The science of ethnobotany is reviewed in light of its multidisciplinary contributions to natural product research for the development of pharmaceuticals and pharmacological tools. Some of the issues reviewed involve ethical and cultural perspectives of healthcare and medicinal plants. While these are not usually part of the discussion of pharmacology, cultural concerns potentially provide both challenges and insight for field and laboratory researchers. Plant evolutionary issues are also considered as they relate to development of plant chemistry and accessing this through ethnobotanical methods. The discussion includes presentation of a range of CNS-active medicinal plants that have been recently examined in the field, laboratory and/or clinic. Each of these plants is used to illustrate one or more aspects about the valuable roles of ethnobotany in pharmacological research.
    [Show full text]
  • Quality Use of Medicines in Residential Aged Care
    RESEARCH Quality use of medicines in Michael Somers residential aged care Ella Rose Dasha Simmonds Claire Whitelaw Janine Calver Christopher Beer Background Approximately 190 000 people in high risk of ADEs in frail older people. For example, Older people are more likely to be Australia were estimated to have anticholinergic drugs commonly produce adverse exposed to polypharmacy. People dementia in 2006, with the prevalence effects in elderly people and are more likely to be with dementia, especially those living expected to increase to 465 000 by 2031.1 prescribed to people with dementia than those in residential aged care facilities The prevalence of dementia increases without.7 (RACFs), are at particularly high risk of with age, from 6.5% of Australians aged Antipsychotic medications are commonly used medication harm. We sought to describe medications prescribed for a sample of 65 years and over to 22% of Australians to manage the behavioural and psychological 2 people with dementia living in RACFs. aged 85 years and over. Dementia is symptoms of dementia (BPSD), such as associated with a large burden of disease psychosis, depression, agitation, aggression Methods in Australia’s aging population, costing and disinhibition.1,8 There is concern that A total of 351 residents with dementia Australia $1.4 billion in 2003.2 Most of this antipsychotics are used too frequently as a aged over 65 years were recruited from 36 RACFs in Western Australia. burden was associated with residential first line treatment for BPSD, with the risks of 2 Data on all medications prescribed aged care facilities (RACFs). Dementia antipsychotic use outweighing the benefits at their were collected, including conventional is the medical problem most frequently likely level of use.8 For example, risperidone, an medications, herbal medications, managed by general practitioners atypical antipsychotic prescribed frequently for the vitamins and minerals.
    [Show full text]
  • Health and Social Outcomes Associated with High-Risk Alcohol Use
    Manitoba Centre for Health Policy Health and Social Outcomes Associated with High-Risk Alcohol Use Summer 2018 Nathan C Nickel, MPH, PhD Jeff Valdivia, MNRM, CAPM Deepa Singal, PhD James Bolton, MD Christine Leong, PharmD Susan Burchill, BMus Leonard MacWilliam, MSc, MNRM Geoffrey Konrad, MD Randy Walld, BSc, BComm (Hons) Okechukwu Ekuma, MSc Greg Finlayson, PhD Leanne Rajotte, BComm (Hons) Heather Prior, MSc Josh Nepon, MD Michael Paille, BHSc This report is produced and published by the Manitoba Centre for Health Policy (MCHP). It is also available in PDF format on our website at: http://mchp-appserv.cpe.umanitoba.ca/deliverablesList.html Information concerning this report or any other report produced by MCHP can be obtained by contacting: Manitoba Centre for Health Policy Rady Faculty of Health Sciences Max Rady College of Medicine, University of Manitoba 4th Floor, Room 408 727 McDermot Avenue Winnipeg, Manitoba, Canada R3E 3P5 Email: [email protected] Phone: (204) 789-3819 Fax: (204) 789-3910 How to cite this report: Nathan C Nickel, James Bolton, Leonard MacWilliam, Okechukwu Ekuma, Heather Prior, Jeff Valdivia, Christine Leong, Geoffrey Konrad, Greg Finlayson, Josh Nepon, Deepa Singal, Susan Burchill, Randy Walld, Leanne Rajotte, Michael Paille. Health and Social Outcomes Associated with High-Risk Alcohol Use. Winnipeg, MB. Manitoba Centre for Health Policy, Summer 2018. Legal Deposit: Manitoba Legislative Library National Library of Canada ISBN 978-1-896489-90-2 ©Manitoba Health This report may be reproduced, in whole or in part, provided the source is cited. 1st printing (Summer 2018) This report was prepared at the request of Manitoba Health, Seniors and Active Living (MHSAL), a department within the Government of Manitoba, as part of the contract between the University of Manitoba and MHSAL.
    [Show full text]
  • PHRP March 2015
    March 2015; Vol. 25(2):e2521518 doi: http://dx.doi.org/10.17061/phrp2521518 www.phrp.com.au Research Manual versus automated coding of free-text self-reported medication data in the 45 and Up Study: a validation study Danijela Gnjidica,b,i, Sallie-Anne Pearsona,c, Sarah N Hilmerb,d, Jim Basilakise, Andrea L Schaffera, Fiona M Blythb,f,g and Emily Banksg,h, on behalf of the High Risk Prescribing Investigators a Faculty of Pharmacy, University of Sydney, NSW, Australia b Sydney Medical School, University of Sydney, NSW, Australia c Sydney School of Public Health, University of Sydney, NSW, Australia d Royal North Shore Hospital and Kolling Institute of Medical Research, Sydney, NSW, Australia e School of Computing, Engineering and Mathematics, University of Western Sydney, NSW, Australia f Centre for Education and Research on Ageing (CERA), Concord Hospital, Sydney, NSW, Australia g The Sax Institute, Sydney, NSW, Australia h National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT i Corresponding author: [email protected] Article history Abstract Publication date: March 2015 Background: Increasingly, automated methods are being used to code free- Citation: Gnjidic D, Pearson S, Hilmer S, text medication data, but evidence on the validity of these methods is limited. Basilakis J, Schaffer AL, Blyth FM, Banks E. To examine the accuracy of automated coding of previously keyed Manual versus automated coding of free-text Aim: in free-text medication data compared with manual coding of original self-reported medication data in the 45 and Up Study: a validation study. Public Health handwritten free-text responses (the ‘gold standard’).
    [Show full text]
  • Plant Powers, Poisons, and Herb Craft
    PLANT POWERS, POISONS, AND HERB CRAFT BY DALE PENDELL Foreword by Gary Snyde, $21.95 US In 'Pharmako/Poeia, Dale Pendell offers a mesmerizing guide to psychoactive Alternative plants, from their pharmacological roots to the literary offshoots. "This is a Health/ book," writes Gary Snyder, "about danger: dangerous knowledge, even more Literature dangerous ignorance." Against the greater danger, ignorance, Pendell strikes a formidable blow, as he proves himself a wise and witty guide to our plant teach- ers, their powers and their poisons. "Dale Pendell reactivates the ancient connection between the bardic poet and the shaman. His Pharmako/Poeia is a litany to the secret plant allies that have always accompanied us along the alchemical trajectory that leads to a new and yet authentically archaic future." — Terence McKenna, author of True Hallucinations "Much of our life-force calls upon the plant world for support, in medicines and in foods, as both allies and teachers. Pendell provides a beautifully crafted bridge between these two worlds. The magic he shares is that the voices are spoken and heard both ways; we communicate with plants and they with us. This book is a moving and poetic presentation of this dialogue." — Dr. Alexander T. Shulgin, University of California at Berkeley, Department of Public Health "Pharmako/Poeia is an epic poem on plant humours, an abstruse alchemic treatise, an experiential narrative jigsaw puzzle, a hip and learned wild-nature reference text, a comic paean to cosmic consciousness, an ecological handbook, a dried-herb pastiche, a countercultural encyclopedia of ancient fact and lore that cuts through the present 'conservative' war-on-drugs psychobabble." - Allen Ginsberg, poet Cover design "Dale PendelFs remarkable book will make it impossible to and color work ever again underestimate the most unprepossessing plant.
    [Show full text]
  • Development of a Multivariable Prediction Model for Identification of Patients at Risk for Medication Transfer Errors at ICU Discharge
    RESEARCH ARTICLE Development of a multivariable prediction model for identification of patients at risk for medication transfer errors at ICU discharge 1,2 1,3 2,4 Liesbeth B. E. BosmaID *, Nienke van Rein , Nicole G. M. Hunfeld , Ewout W. Steyerberg5, Piet H. G. J. Melief6, Patricia M. L. A. van den Bemt2 1 Haga Teaching Hospital, Department of Clinical Pharmacy, Els Borst-Eilersplein CH, The Hague, The Netherlands, 2 Erasmus University Medical Center, Department of Hospital Pharmacy, CA, Rotterdam, The Netherlands, 3 Leiden University Medical Center, Department of Clinical Pharmacy and Toxicology, Leiden, The Netherlands, 4 Erasmus University Medical Center, Department of Intensive Care, CA, Rotterdam, The a1111111111 Netherlands, 5 Clinical Biostatistics and Medical Decision Making at Erasmus MC, Rotterdam and Leiden a1111111111 University Medical Center, ZA Leiden, The Netherlands, 6 Haga Teaching Hospital, Department of Intensive Care, CH, The Hague, The Netherlands a1111111111 a1111111111 * [email protected] a1111111111 Abstract OPEN ACCESS Introduction Citation: Bosma LBE, van Rein N, Hunfeld NGM, Steyerberg EW, Melief PHGJ, van den Bemt PMLA Discharge from the intensive care unit (ICU) is a high-risk process, leading to numerous (2019) Development of a multivariable prediction potentially harmful medication transfer errors (PH-MTE). PH-MTE could be prevented by model for identification of patients at risk for medication reconciliation by ICU pharmacists, but resources are scarce, which renders the medication transfer errors at ICU discharge. PLoS ONE 14(4): e0215459. https://doi.org/10.1371/ need for predicting which patients are at risk for PH-MTE. The aim of this study was to journal.pone.0215459 develop a prognostic multivariable model in patients discharged from the ICU to predict who Editor: Shane Patman, University of Notre Dame is at increased risk for PH-MTE after ICU discharge, using predictors of PH-MTE that are Australia, AUSTRALIA readily available at the time of ICU discharge.
    [Show full text]
  • Online Appendix
    The More We Die, The More We Sell? A Simple Test of the Home-Market Effect Online Appendix Arnaud Costinot Dave Donaldson MIT, CEPR, and NBER MIT, CEPR, and NBER Margaret Kyle Heidi Williams Mines ParisTech and CEPR MIT and NBER December 28, 2018 1 Contents A Theoretical Appendix3 A.1 Multinational Enterprises (Section III.1)..........................3 A.2 Log-Linearization (Section III.2)...............................3 A.3 Beyond Perfect Competition (Section III.3).........................6 A.3.1 Monopolistic Competition..............................6 A.3.2 Variable Markups...................................7 A.3.3 Endogenous Innovation...............................8 A.3.4 Price Regulations...................................9 A.4 Bilateral Sales (Section VI.1)................................. 12 B Empirical Appendix 12 B.1 Rich versus Poor Countries................................. 12 B.2 Additional Empirical Results................................ 13 B.3 Benchmarking IMS MIDAS data.............................. 13 B.3.1 Benchmarking to the OECD HealthStat Data................... 13 B.3.2 Benchmarking to the MEPS Data.......................... 14 B.4 ATC to GBD Mapping.................................... 15 2 A Theoretical Appendix A.1 Multinational Enterprises (Section III.1) In this appendix, we illustrate how to incorporate multinational production into our basic envi- ronment. Following Ramondo and Rodríguez-Clare(2013), suppose that each firm headquartered in country i that sells drugs targeting disease n in country j 6= i can choose the country l in which its production takes place. If l = i, then the firm exports, if l = j, it engages in horizontal FDI, and if l 6= i, j, it engages in platform FDI. Like in Ramondo and Rodríguez-Clare(2013), we assume that firm-level production functions exhibit constant returns to scale, but we further allow for external economies of scale at the level of the headquarter country for each disease.
    [Show full text]
  • BULGARIA New Development, Trends and In-Depth Information on Selected Issues
    2007 NATIONAL REPORT (2006 data) TO THE EMCDDA by the Reitox National Focal Point BULGARIA New Development, Trends and in-depth information on selected issues REITOX 1 TABLES OF CONTENTS Summary..........................................................................................................................3 Part A: New Trends and Developments 1. National Policies and Context ......................................................................................8 2. Drug use in the General Population and Specific Sub-groups ...................................21 3. Prevention ..................................................................................................................29 4. Problem Drug Use......................................................................................................39 5. Drug-Related Treatment.............................................................................................47 6. Health Correlates and Consequences........................................................................51 7. Responses to Health Correlates and Consequences.................................................65 8. Social correlates and consequences..........................................................................72 9. Response to social correlates and consequences .....................................................82 10. Drug Markets............................................................................................................88 Part B: Selected issues 12. Vulnerable Groups of
    [Show full text]
  • Anatomical Classification Guidelines V2020 EPHMRA ANATOMICAL
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2020 Anatomical Classification Guidelines V2020 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2020 Anatomical Classification Guidelines V2020 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 35 D DERMATOLOGICALS 50 G GENITO-URINARY SYSTEM AND SEX HORMONES 57 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 65 J GENERAL ANTI-INFECTIVES SYSTEMIC 69 K HOSPITAL SOLUTIONS 84 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 92 M MUSCULO-SKELETAL SYSTEM 102 N NERVOUS SYSTEM 107 P PARASITOLOGY 118 R RESPIRATORY SYSTEM 120 S SENSORY ORGANS 132 T DIAGNOSTIC AGENTS 139 V VARIOUS 141 Anatomical Classification Guidelines V2020 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system.
    [Show full text]
  • Analyses of Spontaneous Adverse Drug Reaction Databases Using Descriptive and Inferential Statistics
    Analyses of Spontaneous Adverse Drug Reaction Databases Using Descriptive and Inferential Statistics Dissertation zur Erlangung des Doktorgrades (PhD) der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn Diana Ivonne Dubrall aus Heidenheim an der Brenz 2020 Angefertigt mit der Genehmigung der Medizinischen Fakultät der Universität Bonn 1. Gutachter: Prof. Dr. rer. nat. Matthias Schmid 2. Gutachter: Prof. Dr. med. Bernhardt Sachs Tag der mündlichen Prüfung: 04.09.2020 Aus dem Institut für Medizinische Biometrie, Informatik und Epidemiologie Direktor: Prof. Dr. rer. nat. Matthias Schmid 3 Table of content Table of content ........................................................................................................ 3 List of abbreviations ................................................................................................. 4 1. Summary ............................................................................................................... 5 2. Introduction ........................................................................................................... 5 3. Objectives ............................................................................................................. 8 4. Methods ................................................................................................................. 8 4.1 BfArM’s ADR database ...................................................................................... 8 4.2 EudraVigilance .................................................................................................
    [Show full text]
  • A Chemoinformatics Approach for the in Silico Identification of Interactions Between Psychiatric Drugs and Plant-Based Food
    Diploma Thesis A Chemoinformatics Approach for the In Silico Identification of Interactions Between Psychiatric Drugs and Plant-Based Food Anna Maria Tsakiroglou Thesis Supervisors: Assoc. Prof.: Kouskoumvekaki Irene Assoc. Prof.: Topakas Evangelos February 2016 Dedication To all the people who made the realization of this work possible. My supervisor for the most useful input and advice along the way. My parents for their unending support. To Katerina, and last, but not least, to Panagiotis, for always being there for me, even from so far away. You are awesome. i ii Abstract The overall objective of this project was the development of a systematic approach for identifying potential interactions between plant-based food and marketed psycholeptics and psychoanaleptic drugs. The problem was addressed, initially, by pairing psychiatric agents and phytochemicals to their common protein targets, using information available in online databases, such as NutriChem 1.0 [21] and Drugbank [16] and constructing the food-drug interaction networks. Thereupon, a search for additional phytochemicals that would be expected to interact with targets of psychiatric drugs was carried out. More specifically, three protein targets, P07550, P28222 and P14416 were selected, based on their frequency of interaction with both psycholeptics and psychoanaleptics and the avail- ability of 3D structural information in PDB [19]. For these protein targets, ligand-based pharmacophoric hypothesis were generated, using experimental activity data from the literature, and the HypoGen feature of Accelrys Discovery Studio (DS) [7]. The phar- macophore models were validated using external test sets and Fisher’s method. Sub- sequently, the models were used as queries to screen the NutriChem 1.0 database for more potentially active phytochemicals.
    [Show full text]
  • Nervous System Drug Poster
    Nervous System Drugs Created by the Njardarson Group (The University of Arizona): Edon Vitaku, Elizabeth A. Ilardi, Daniel J. Mack, Monica A. Fallon, Erik B. Gerlach, Miyant’e Y. Newton, Angela N. Yazzie, Jack Siqueiros, Jón T. Njarðarson Cocaine Aspirin Caffeine Procaine Benzocaine Metharbital Oxycodone Disulfiram Morphine Ergotamine Hydromorphone Codeine Pemoline Amphetamine Thiopental Methadone Methadone Biperiden Thiopental D.H.E. Trimethadione Urecholine Cafergot ( Cocaine ) ( Aspirin ) ( Caffeine ) ( Procaine ) ( Benzocaine ) ( Metharbital ) ( Oxycodone ) ( Disulfiram ) ( Morphine ) ( Ergotamine ) ( Hydromorphone ) ( Codeine ) ( Pemoline ) ( Amphetamine ) ( Thiopental ) ( Methadone ) ( Methadone ) ( Biperiden ) ( Thiopental ) ( Dihydroergotamine ) ( Trimethadione ) ( Bethanechol ) ( Ergotamine & Caffeine ) ANESTHETIC ANALGESIC PSYCHOANALEPTIC ANESTHETIC ANESTHETIC ANTIEPILEPTIC ANALGESIC MISC. NERVOUS ANALGESIC ANALGESIC ANALGESIC ANALGESIC PSYCHOANALEPTIC PSYCHOANALEPTIC ANESTHETIC ANALGESIC MISC. NERVOUS ANTI-PARKINSON PSYCHOLEPTIC ANALGESIC ANTIEPILEPTIC MISC. NERVOUS ANALGESIC Approved 1880 Approved 1899 Approved 1900 Approved 1900 Approved 1902 Approved 1905 Approved 1916 Approved 1920 Approved 1920 Approved 1921 Approved 1926 Approved 1930 Approved 1930 Approved 1933 Approved 1934 Approved 1937 Approved 1937 Approved 1940 Approved 1940 Approved 1946 Approved 1947 Approved 1948 Approved 1948 Lidocaine Artane Anileridine Chlor-Trimeton Clonidine Ethchlorvynol Imipramine Morphine Percodan Paramethadione Secobarbital Apomorphine
    [Show full text]